Clinical Utility of CTC Test in Medicare-Eligible Metastatic Breast Cancer Patients
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Breast Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 65 - Any |
| Updated: | 7/11/2015 |
| Start Date: | January 2015 |
| End Date: | May 2017 |
| Contact: | Alberto Montero, MD |
| Email: | montero2@ccf.org |
Registry to Demonstrate the Clinical Utility of CELLSEARCH® Circulating Tumor Cell (CTC) Test in Medicare-Eligible Metastatic Breast Cancer Patients
The objective of the registry study is to demonstrate the clinical utility of the
CELLSEARCH® CTC Test among the Medicare-Eligible metastatic Breast Cancer (mBC) patients in
the United States. The objective of the present registry is to demonstrate the impact on
patient management of the CELLSEARCH® CTC Test among the Medicare-eligible mBC patients.
Hereto the hypothesis that the availability of CTC information provides clinicians
important, timely information and changes treatment decisions, will be tested.
This study is IDE-exempt since CELLSEARCH® CTC Test is a legally marketed device in the US,
and is being used in accordance with its labeling.
CELLSEARCH® CTC Test among the Medicare-Eligible metastatic Breast Cancer (mBC) patients in
the United States. The objective of the present registry is to demonstrate the impact on
patient management of the CELLSEARCH® CTC Test among the Medicare-eligible mBC patients.
Hereto the hypothesis that the availability of CTC information provides clinicians
important, timely information and changes treatment decisions, will be tested.
This study is IDE-exempt since CELLSEARCH® CTC Test is a legally marketed device in the US,
and is being used in accordance with its labeling.
Inclusion Criteria:
Patient has documented (histologically/pathologically confirmed) mBC diagnosis
- Patient is at least 65 years of age at time of mBC diagnosis
- Patient is female
- Patient is being actively treated at the cancer center by a physician who uses or
plans to use CTC testing on his mBC patients at lease every quarter.
Exclusion Criteria:
- Patients breast cancer is secondary not primary
We found this trial at
2
sites
3400 Civic Center Blvd
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
(215) 662-6065
Abramson Cancer Center of the University of Pennsylvania The Abramson Cancer Center of the University...
Click here to add this to my saved trials
Thomas Jefferson University We are dedicated to the health sciences and committed to educating professionals,...
Click here to add this to my saved trials